Literature DB >> 30308517

Shufeng Jiedu Capsules Alleviate Lipopolysaccharide-Induced Acute Lung Inflammatory Injury via Activation of GPR18 by Verbenalin.

Ying Yuan1, Qingwu Liao2, Mingming Xue3, Yujing Shi4, Ling Rong5, Zhenju Song3, Zhaoyang Tong3, Wuhong Zheng6, Qiang Zhu7, Xiaolan Cui4, Zhengang Tao3.   

Abstract

BACKGROUND/AIMS: Acute respiratory tract infection (ARTI) is the most common reason for outpatient physician office visits. Although powerful and significant in the treatment of infections, antibiotics used for ARTI inappropriately have been an important contributor to antibiotic resistance. We previously reported that Shufeng Jiedu Capsule (SJC) can effectively amplify anti-inflammatory signaling during infection. In this study, we aimed to systematically explore its composition and the mechanism of its effects in ARTI.
METHODS: Pseudomonas aeruginosa (PAK) strain was used to generate a mouse model of ARTI, which were then treated with different drugs or compounds to determine the corresponding anti-inflammatory roles. High-performance liquid chromatography-quadrupole time of flight-tandem mass spectrometry. was conducted to detect the chemical compounds in SJC. RNAs from the lung tissues of mice were prepared for microarray analysis to reveal globally altered genes and the pathways involved after SJC treatment.
RESULTS: SJC significantly inhibited the expression and secretion of inflammatory factors from PAK-induced mouse lung tissues or lipopolysaccharide-induced peritoneal macrophages. Verbenalin, one of the bioactive compounds identified in SJC, also showed notable anti-inflammatory effects. Microarray data revealed numerous differentially expressed genes among the different treatment groups; here, we focused on studying the role of GPR18. We found that the anti-inflammatory role of verbenalin was attenuated in GPR18 knockout mice compared with wild-type mice, although no statistically significant difference was observed in the untreated PAK-induced mice types.
CONCLUSION: Our data not only showed the chemical composition of SJC, but also demonstrated that verbenalin was a significant anti-inflammatory compound, which may function through GPR18.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute respiratory tract infection; GPR18; Peritoneal macrophages; Shufeng Jiedu Capsule; Verbenalin

Mesh:

Substances:

Year:  2018        PMID: 30308517     DOI: 10.1159/000494184

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

1.  Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Xiao-Wen Zhang; Ru-Yu Xia; Jia-Qi Gao; Jin-Jun Liu; De-Hao Xu; Xun Li; Xiao-Yang Hu; Merlin Willcox; Michael Moore; Meng-Yuan Dai; Jeanne Trill; Yu-Tong Fei; Jian-Ping Liu
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

Review 2.  Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.

Authors:  Fiona Limanaqi; Carla Letizia Busceti; Francesca Biagioni; Gloria Lazzeri; Maurizio Forte; Sonia Schiavon; Sebastiano Sciarretta; Giacomo Frati; Francesco Fornai
Journal:  Antioxidants (Basel)       Date:  2020-11-10

3.  Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.

Authors:  Jing Chen; Shaowu Lin; Conway Niu; Qi Xiao
Journal:  Expert Rev Respir Med       Date:  2020-09-17       Impact factor: 3.772

4.  Efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.

Authors:  Huijun Ren; Yuhao Jiang; Shiyu Wang; Yirong Wang; Jingying Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-08       Impact factor: 1.817

5.  The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge.

Authors:  Lu Xia; Jun Chen; Thomas Friedemann; Zongguo Yang; Yun Ling; Xuhui Liu; Shuihua Lu; Tao Li; Zhigang Song; Wei Huang; Yunfei Lu; Sven Schröder; Hongzhou Lu
Journal:  Open Forum Infect Dis       Date:  2020-07-23       Impact factor: 3.835

Review 6.  Bioactive natural compounds against human coronaviruses: a review and perspective.

Authors:  Yanfang Xian; Juan Zhang; Zhaoxiang Bian; Hua Zhou; Zhenbiao Zhang; Zhixiu Lin; Hongxi Xu
Journal:  Acta Pharm Sin B       Date:  2020-06-08       Impact factor: 11.413

7.  Efficacy and safety of Shufeng Jiedu capsule in the treatment of COVID-19: A protocol for systematic review and meta analysis.

Authors:  Li Ma; Ji-Ni Song; Yan-Ping Song; Lin-Tao Zhao; Hao Chen
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.